Kidney360 Publish Ahead of Print, published on June 16, 2021 as doi:10.34067/KID.0002432021 Bleeding complications of percutaneous kidney biopsy: Does gender matter? Aksharaa Anpalahan1, Eva Malacova2, Katharine Hegerty3, Andrew Malett4,5, Dwarakanathan Ranganathan1, Helen G Healy1,5,6, Pedro Henrique Franca Gois1,5,6 1Royal Brisbane and Women’s Hospital, Brisbane, QLD 4029, Australia 2Queensland Institute of Medical Research, Brisbane, QLD 4029, Australia 3Metro South and Integrated Nephrology and Transplant Services, Princess Alexandra Hospital, Brisbane, QLD 4074, Australia 4Department of Renal Medicine, Townsville University Hospital, Townsville, QLD 4814, Australia 5Faculty of Medicine, University of Queensland, Brisbane, QLD 4006, Australia 6Conjoint Kidney Research Laboratory, Chemical Pathology—Pathology Queensland, Brisbane, QLD 4029, Australia *Correspondence: Aksharaa Anpalahan, Royal Brisbane and Women’s Hospital Butterfield St, Herston QLD 4029 Email:
[email protected] Phone: 0422282515 Copyright 2021 by American Society of Nephrology. Key Points The incidence of bleeding complications post percutaneous kidney biopsies is low. Female gender may be associated with a greater risk for bleeding complications post percutaneous kidney biopsies. This association and the plausible mechanisms requires further evaluation in prospective studies. Introduction Percutaneous Kidney Biopsies (PKBs) are the gold standard for investigating renal parenchymal diseases. Although PKBs are generally considered a low-risk procedure, particularly with the advances in real-time ultrasonography and automated spring-loaded biopsy devices, they still carry risks of bleeding of a severity that prolongs hospital stay and increases treatment costs. Management of post-biopsy bleeding may include transfusion of blood products, which represents an additional burden of sensitization subsequently increasing the immunologic risk for future kidney transplant in individuals with kidney diseases1,2 .